Linagliptin Viatris

Linagliptin, the active ingredient in Linagliptin Viatris, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control when used with diet and exercise, and is indicated for patients who require additional glycemic control beyond lifestyle measures.

GNH USA supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under GMP conditions.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycemic control as monotherapy when diet and exercise are insufficient. - Combination therapy: added to metformin, sulfonylureas or insulin to further lower HbA1c. - Adjunct to lifestyle: used alongside diet and exercise to achieve target blood glucose levels.

Linagliptin may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection. - Headache: transient mild to moderate pain. - Gastrointestinal upset: includes nausea, abdominal pain or diarrhoea. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia: especially when combined with sulfonylureas or insulin.

When prescribing Linagliptin, consider the following precautions to ensure safe use.

- Renal impairment: monitor kidney function regularly. - Hepatic impairment: use with caution and assess liver enzymes. - Cardiovascular disease: no dose adjustment required but monitor for symptoms. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Drug interactions: review concomitant medications for potential additive hypoglycaemia. - Store at ambient temperature: keep in original container, protect from moisture and light.

Linagliptin can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Sulfonylureas or insulin: may increase risk of hypoglycaemia; dose adjustment required. - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure and efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glucose control, monitor blood sugar. - ACE inhibitors or ARBs: additive antihyperglycaemic effect possible. - Anticoagulants: monitor INR as glycaemic changes can influence clotting. - Oral contraceptives: may have altered plasma levels; observe clinical response.